ArticleThe Journal of experimental medicine2000
Viral escape by selection of cytotoxic T cell-resistant variants in influenza A virus pneumonia.
Article in The Journal of experimental medicine, 2000. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
52 citing papers in PubMed, 101 citations in OpenAlex.
- Single-cycle influenza virus vaccine generates lung CD8Science advances · 2023Article
- Review
- A ribavirin-induced ORF2 single-nucleotide variant produces defective hepatitis E virus particles with immune decoy function.Proceedings of the National Academy of Sciences of the United States of America · 2022Article
- SARS-CoV-2 Omicron variant escapes neutralizing antibodies and T cell responses more efficiently than other variants in mild COVID-19 convalescents.Cell reports. Medicine · 2022Article
- Evolutionary conservation and positive selection of influenza A nucleoprotein CTL epitopes for universal vaccination.Journal of medical virology · 2022Article
- Next-generation T cell-activating vaccination increases influenza virus mutation prevalence.Science advances · 2022Article
- Features of HLA class I expression and its clinical relevance in SARS-CoV-2: What do we know so far?Reviews in medical virology · 2021Review
- TCR Transgenic Mice: A Valuable Tool for Studying Viral Immunopathogenesis Mechanisms.International journal of molecular sciences · 2020Review
- Tuning antiviral CD8 T-cell response via proline-altered peptide ligand vaccination.PLoS pathogens · 2020Article
- Article
- Comprehensive profiling of translation initiation in influenza virus infected cells.PLoS pathogens · 2019Article
- Variation at Extra-epitopic Amino Acid Residues Influences Suppression of Influenza Virus Replication by M1Journal of virology · 2018Article
- Harnessing the Power of T Cells: The Promising Hope for a Universal Influenza Vaccine.Vaccines · 2018Review
- Innate and adaptive T cells in influenza disease.Frontiers of medicine · 2018Review
- Long-term adaptation of the influenza A virus by escaping cytotoxic T-cell recognition.Scientific reports · 2016Article
- Analyzing the effect of peptide-HLA-binding ability on the immunogenicity of potential CD8+ and CD4+ T cell epitopes in a large dataset.Immunologic research · 2016Article
- Positive Selection in CD8+ T-Cell Epitopes of Influenza Virus Nucleoprotein Revealed by a Comparative Analysis of Human and Swine Viral Lineages.Journal of virology · 2015Article
- Epitope-optimized alpha-fetoprotein genetic vaccines prevent carcinogen-induced murine autochthonous hepatocellular carcinoma.Hepatology (Baltimore, Md.) · 2014Article
- Memory CD4 T cell-mediated immunity against influenza A virus: more than a little helpful.Archivum immunologiae et therapiae experimentalis · 2013Review
- Multipronged CD4(+) T-cell effector and memory responses cooperate to provide potent immunity against respiratory virus.Immunological reviews · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Antigenic variation is a strategy exploited by influenza viruses to promote survival in the face of the host adaptive immune response and constitutes a major obstacle to efficient vaccine development. Thus, variation in the surface glycoproteins hemagglutinin and neuraminidase is reflected by changes in susceptibility to antibody neutralization. This has led to the current view that antibody-mediated selection of influenza A viruses constitutes the basis for annual influenza epidemics and periodic pandemics. However, infection with this virus elicits a vigorous protective CD8(+) cytotoxic T lymphocyte (CTL) response, suggesting that CD8(+) CTLs might exert selection pressure on the virus. Studies with influenza A virus-infected transgenic mice bearing a T cell receptor (TCR) specific for viral nucleoprotein reveal that virus reemergence and persistence occurs weeks after the acute infection has apparently been controlled. The persisting virus is no longer recognized by CTLs, indicating that amino acid changes in the major viral nucleoprotein CTL epitope can be rapidly accumulated in vivo. These mutations lead to a total or partial loss of recognition by polyclonal CTLs by affecting presentation of viral peptide by class I major histocompatibility complex (MHC) molecules, or by interfering with TCR recognition of the mutant peptide-MHC complex. These data illustrate the distinct features of pulmonary immunity in selection of CTL escape variants. The likelihood of emergence and the biological impact of CTL escape variants on the clinical outcome of influenza pneumonia in an immunocompetent host, which is relevant for the design of preventive vaccines against this and other respiratory viral infections, are discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.